Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2025-06-24 00:00:00 ET · period of report 2025-06-20 · accession 0001628280-25-032855 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-24 | 2025-06-20 | MDGL | FOUSE JACQUALYN A | Dir | A - Grant | $0.00 | +203 | 1,097 | +23% | $0 |
| D | 2025-06-24 | 2025-06-20 | MDGL | FOUSE JACQUALYN A | Dir | A - Grant | $0.00 | +366 | 366 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-20 | A | A | 203 | $0.00 | 1,097 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-06-20 | A | A | 366 | $0.00 | 366 | D | $285.73 · — to 2035-06-20 | 366 Common Stock | (F2) The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date. |